PLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

California, USA-based fibrosis specialist Pliant Therapeutics saw its shares leap 20.95% to $3.29 by close of trading ...

Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...

Highlights,Pliant Therapeutics has received mixed assessments from financial institutions, leading to adjustments in price targets.,Recent rating downgrades from major research firms have ...

Fintel reports that on February 10, 2025, Citigroup downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.